The estimated Net Worth of Mahiuddin Ahmed is at least $6.3 Milion dollars as of 26 May 2020. Mahiuddin Ahmed owns over 50,000 units of Y-Mabs Therapeutics Inc stock worth over $1,990,500 and over the last 5 years he sold YMAB stock worth over $4,310,306. In addition, he makes $0 as Senior Vice President a Chief Scientific Officer at Y-Mabs Therapeutics Inc.
Sign up
Mahiuddin Ahmed YMAB stock SEC Form 4 insiders trading
Mahiuddin has made over 4 trades of the Y-Mabs Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently he sold 50,000 units of YMAB stock worth $1,969,000 on 26 May 2020.
The largest trade he's ever made was selling 50,000 units of Y-Mabs Therapeutics Inc stock on 26 May 2020 worth over $1,969,000. On average, Mahiuddin trades about 27,500 units every 4 days since 2020. As of 26 May 2020 he still owns at least 150,000 units of Y-Mabs Therapeutics Inc stock.
You can see the complete history of Mahiuddin Ahmed stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Mahiuddin Ahmed biography
Dr. Mahiuddin Ahmed Ph.D. serves as Senior Vice President, Chief Scientific Officer of the Company. Dr. Ahmed joined our Company in March 2018 as Vice President and Chief Scientific Officer and since January 1, 2020 has been Senior Vice President and Chief Scientific Officer. Dr. Ahmed is an expert in antibody and therapeutic protein engineering based on in silico design. He received his Ph.D in Biochemistry and Structural Biology from Stony Brook University and completed postdoctoral training in cancer immunotherapy at the Sloan Kettering Institute. He was formerly a faculty member in the Department of Pediatrics at Memorial Sloan Kettering and is an inventor of numerous issued and pending patents related to therapeutic proteins, bispecific antibodies, radioimmunotherapy products and related technologies. Dr. Ahmed oversees our Research & Development Laboratories in Nutley, New Jersey.
How old is Mahiuddin Ahmed?
Mahiuddin Ahmed is 41, he's been the Senior Vice President a Chief Scientific Officer of Y-Mabs Therapeutics Inc since 2020. There are 18 older and no younger executives at Y-Mabs Therapeutics Inc. The oldest executive at Y-Mabs Therapeutics Inc is Dr. Torben Lund-Hansen, 70, who is the Sr. VP & Chief Technical Officer.
What's Mahiuddin Ahmed's mailing address?
Mahiuddin's mailing address filed with the SEC is C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK, NY, 10169.
Insiders trading at Y-Mabs Therapeutics Inc
Over the last 6 years, insiders at Y-Mabs Therapeutics Inc have traded over $85,284,951 worth of Y-Mabs Therapeutics Inc stock and bought 1,819,126 units worth $23,554,756 . The most active insiders traders include James Healy, Thomas Gad a Johan Wedell Wedellsborg. On average, Y-Mabs Therapeutics Inc executives and independent directors trade stock every 14 days with the average trade being worth of $494,414. The most recent stock trade was executed by Torben Lund Hansen on 28 August 2024, trading 50,000 units of YMAB stock currently worth $219,000.
What does Y-Mabs Therapeutics Inc do?
y-mabs is late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. the company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates - naxitamab and omburtamab - which target tumors that express gd2 and b7-h3, respectively. our mission is to become the world leader in developing antibody-based cancer products that address clear unmet needs in pediatric oncology. with the right partnerships and collaboration, we envision expanding our capabilities to treat adults - changing the course of cancer and its outcome.
What does Y-Mabs Therapeutics Inc's logo look like?
Complete history of Mahiuddin Ahmed stock trades at Y-Mabs Therapeutics Inc
Y-Mabs Therapeutics Inc executives and stock owners
Y-Mabs Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Dr. Claus Juan Møller San Pedro M.D., Ph.D.,
CEO & Director -
Claus Moller-San Pedro,
Chief Executive Officer, Director -
Thomas Gad,
Chairman of the Board, President, Founder, Head of Business Development and Strategy -
Thomas Gad,
Founder, Chairman, Pres and Head of Bus. Devel. & Strategy -
Bo Kruse,
Chief Financial Officer, Executive Vice President, Treasurer, Secretary, Director -
Bo Kruse,
Exec. VP, Sec., Treasurer & CFO -
David Gill,
Independent Director -
James Healy,
Independent Director -
Ashutosh Tyagi,
Independent Director -
Gerard Ber,
Independent Director -
Johan Wedell-Wedellsborg,
Independent Director -
Torben Lund-Hansen,
Senior Vice President, Chief Technical Officer -
Steen Lisby,
Senior Vice President, Chief Medical Officer -
Philip Herman,
Senior Vice President and Chief Commercial Officer -
Mahiuddin Ahmed,
Senior Vice President, Chief Scientific Officer -
Joris Wilms,
Chief Operating Officer, Senior Vice President -
Sue Smith,
Sr. VP & Chief Commercial Officer -
Dr. Torben Lund-Hansen,
Sr. VP & Chief Technical Officer -
Joris Wiel Jan Wilms,
Sr. VP & COO -
Dr. Vignesh Rajah,
Sr. VP & Chief Medical Officer -
Dr. Steen Lisby M.D., M.Sc.,
Sr. VP & Chief Scientific Officer -
Peter P. Pfreundschuh,
CFO and Treasurer -
Gregory S Raskin,
Director -
Ashu Tyagi,
Director -
Mary Tagliaferri,
Director -
Laura Hamill,
Director -
Vignesh Rajah,
SVP & CHIEF MEDICAL OFFICER -
Biotech Ap S Wg,
Director -
Susan Laura Smith,
SVP & CHIEF COMMERCIAL OFFICER -
Michael J Rossi,
PRESIDENT & CEO